Argatroban in short-term percutaneous ventricular assist subsequent to heparin-induced thrombocytopenia.
Heparin-induced thrombocytopenia paradoxically is a transient pro-thrombotic disorder triggered by heparin exposure. If not treated appropriately, it can be life threatening because of its related thromboembolic complications. In particular, it presents a unique challenge in patients needing extracorporeal life support, because anticoagulation is essential for safe management. This case report describes the safe, efficacious use of Argatroban during short-term support of a patient with a percutaneously inserted left ventricular assist TandemHeart device.
Webb
David P
DP
Vanderbilt Heart Institute, Division of Perfusion Services, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA. david.webb@vanderbilt.edu
Warhoover
Matthew T
MT
Eagle
Susan S
SS
Greelish
James P
JP
Zhao
David X
DX
Byrne
John G
JG
D000328:Adult; D001120:Arginine / Q000031:analogs & derivatives; D005343:Fibrinolytic Agents / Q000009:adverse effects*; D006353:Heart-Assist Devices; D006493:Heparin / Q000009:adverse effects*; D006801:Humans; D008297:Male; D010875:Pipecolic Acids / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D010976:Platelet Count; D013449:Sulfonamides; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000188:drug therapy*
D005343:Fibrinolytic Agents; D010875:Pipecolic Acids; D010975:Platelet Aggregation Inhibitors; D013449:Sulfonamides; D006493:Heparin; D001120:Arginine; C031942:argatroban